Two Sigma Advisers’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Two Sigma Advisers’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,120	Closed	-$50K	–	2755
2022 Q3	$50K	Sell	5,120 -220	-4%	-$4.11K	﹤0.01%	2375
2022 Q2	$102K	Sell	5,340 -5,080	-49%	-$132K	﹤0.01%	2389
2022 Q1	$518K	Sell	10,420 -13,060	-56%	-$677K	﹤0.01%	1971
2021 Q4	$1.77M	Sell	23,480 -14,270	-38%	-$974K	﹤0.01%	1258
2021 Q3	$2.98M	Buy	+37,750	New	+$3.79M	0.01%	1041
2021 Q2	–	Sell	-4,340	Closed	-$908K	–	2765
2021 Q1	$908K	Sell	4,340 -1,720	-28%	-$345K	﹤0.01%	1708
2020 Q4	$1.01M	Sell	6,060 -850	-12%	-$131K	﹤0.01%	1566
2020 Q3	$1.17M	Buy	6,910 +4,850	+235%	+$700K	﹤0.01%	1433
2020 Q2	$342K	Buy	2,060 +600	+41%	+$93.6K	﹤0.01%	2063
2020 Q1	$169K	Buy	1,460 +380	+35%	+$53.4K	﹤0.01%	2212
2019 Q4	$160K	Buy	+1,080	New	+$164K	﹤0.01%	2220

Other funds holding HARP

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Two Sigma Advisers's HARP Position: Q4 2022 in Review

Two Sigma Advisers sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2022, closing a stake of 5,120 shares — an estimated $50K sold.

Two Sigma Advisers first reported a position in HARP in Q4 2019 and held it in 11 quarters. The position peaked at $2.98M in Q3 2021. 49 funds tracked by Wall St. Rank hold HARP as of Q4 2022.

Two Sigma Advisers reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 5,120 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $50K.
Two Sigma Advisers first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Two Sigma Advisers's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.98M in Q3 2021.
49 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.